This study checks how well a treatment, combining two medicines called utidelone and capecitabine, works for people with a type of breast cancer that has spread to the brain. These patients have a specific kind of cancer called HER2-negative, meaning it lacks a protein that usually helps cancer grow. The study has two stages to see if this new treatment can help both in the brain and overall in the body. People in the study will get utidelone alone or with capecitabine.
Patients must be adults (18+), have specific cancer characteristics, and be able to visit doctors regularly. They should not have certain other health problems, like uncontrolled seizures or recent surgeries.
- Study duration depends on response and could involve multiple visits.
- Participants will receive utidelone alone or with capecitabine.
- Potential risks include side effects from the medicines.
Doctors will monitor patients to ensure safety and effectiveness. Women and men must use birth control during and after the study, and patients must agree to follow study rules and visit schedules. This study helps understand new treatment possibilities for this serious condition.